Hennion & Walsh Asset Management Inc. Takes Position in Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. acquired a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 4th quarter, Holdings Channel reports. The fund acquired 139,591 shares of the company’s stock, valued at approximately $1,251,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Zevra Therapeutics by 6.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares during the period. Strs Ohio acquired a new position in Zevra Therapeutics during the first quarter worth approximately $125,000. Geode Capital Management LLC raised its stake in Zevra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,242,386 shares of the company’s stock worth $10,948,000 after purchasing an additional 9,275 shares during the period. Creative Planning purchased a new position in Zevra Therapeutics during the second quarter worth approximately $92,000. Finally, Rhumbline Advisers boosted its holdings in shares of Zevra Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company’s stock valued at $733,000 after purchasing an additional 8,636 shares during the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

ZVRA has been the subject of several research analyst reports. Weiss Ratings upgraded Zevra Therapeutics from a “sell (d+)” rating to a “hold (c+)” rating in a research note on Tuesday, March 10th. BTIG Research assumed coverage on Zevra Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $23.00 price objective on the stock. Guggenheim set a $23.00 target price on Zevra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, March 10th. HC Wainwright set a $26.00 target price on shares of Zevra Therapeutics in a research report on Tuesday, December 30th. Finally, Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Zevra Therapeutics Stock Down 0.1%

Shares of NASDAQ ZVRA opened at $9.40 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 5.63 and a current ratio of 5.68. Zevra Therapeutics, Inc. has a 1 year low of $6.19 and a 1 year high of $13.16. The stock’s 50-day simple moving average is $9.10 and its 200-day simple moving average is $9.16. The firm has a market cap of $551.87 million, a price-to-earnings ratio of 7.07 and a beta of 0.89.

Insider Activity

In other Zevra Therapeutics news, insider Joshua Schafer sold 10,500 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $9.19, for a total transaction of $96,495.00. Following the transaction, the insider owned 62,278 shares of the company’s stock, valued at approximately $572,334.82. This trade represents a 14.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Timothy J. Sangiovanni sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $9.18, for a total value of $27,540.00. Following the sale, the senior vice president directly owned 29,590 shares in the company, valued at approximately $271,636.20. The trade was a 9.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 114,158 shares of company stock valued at $1,062,878. Company insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.